All In Biotech

Free tool

FAERS Monitor: Orladeyo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 219776 or its brand name (Orladeyo, Berotralstat Dihydrochloride). Reports on generic versions are filed under their own applications.

Reports

911

Serious

434

48% of reports

Hospitalization

214

Death reported

28

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • hereditary angioedema258
  • nausea63
  • diarrhoea62
  • drug ineffective61
  • headache56
  • abdominal pain52
  • gastrointestinal disorder50
  • condition aggravated47
  • fatigue44
  • vomiting40
  • malaise37
  • abdominal pain upper36
  • covid-1936
  • dizziness32
  • injection site pain31

Reports by year received

View as table
YearReports
20191
20205
202170
202286
2023105
2024201
2025308
2026135

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,248 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hereditary angioedemaSignal258568.7512.0142,220
gastrointestinal disorderSignal5012.99.8539
abdominal painSignal525.24.0172
covid-19Signal364.73.4103
abdominal pain upperSignal364.02.980
condition aggravatedSignal473.62.786
injection site painSignal312.31.723
diarrhoeaSignal622.21.742
headacheSignal562.11.630
vomiting402.01.518
malaise371.91.416
nausea631.81.424
dizziness321.51.15
fatigue441.31.03
drug ineffective611.10.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.